US PTAB IP Litigation
8,722 annotated decisions
Page 248 of 364 · 8,722 total
patent instituted · Aug 3, 2024
Dyson Technology Limited et al. v.Omachron Intellectual Property Inc. et al.
· IPR2024-00670
Dyson Technology Limited successfully established a reasonable likelihood of prevailing in its IPR against Omachron Intellectual Property regarding vacuum cleaner technology. The Board found that combinations of prior art references rendered multiple claims obvious or anticipated.
patent denied · Aug 3, 2024
FERVO ENERGY CO. v.Ormat Technologies, Inc.
· IPR2024-00665
The PTAB denied institution for FERVO ENERGY CO.'s IPR challenge against Ormat Technologies, Inc., finding that the petitioner failed to demonstrate a reasonable likelihood of prevailing. The denial was based on deficiencies in showing obviousness over prior art references like Rinaldi and Swenson.
patent instituted · Aug 3, 2024
Aptiv Services US, LLC et al. v.Microchip Technology, Inc.
· IPR2024-00646
Aptiv Services challenged Microchip Technology's patent (9471074) in an IPR, arguing obviousness over Al-Shyoukh in view of Ivanov and Stanescu. The PTAB institution decision granted the petition, proceeding to trial on 18 claims.
patent denied · Aug 3, 2024
CISCO SYSTEMS, INC. et al. v.InfoExpress Inc.
· IPR2024-00540
The PTAB denied institution of IPR for Cisco and Fortinet against InfoExpress, finding no reasonable likelihood that the challenged claims of U.S. Patent No. 8,347,350 would be found obvious over prior art.
patent final · Aug 3, 2024
Aptiv Services US, LLC et al. v.Microchip Technology, Inc.
· IPR2024-00646
The PTAB found that the claims of the voltage regulator are unpatentable under § 103 based on a combination of Al-Shyoukh and Ivanov. The Board adopted Petitioner's interpretation of key terms, including finding 'gm enhanced' synonymous with 'gm boost.'
patent · Aug 2, 2024
Juniper Networks, Inc. v.Monarch Networking Solutions LLC
· IPR2024-00561
Juniper has filed an IPR petition seeking cancellation of Monarch’s ’775 patent, asserting that claims 1 and 6 are obvious over prior‑art MPLS and pseudo‑wire literature, including Aggarwal’s patent and Hussain’s book.
patent · Aug 2, 2024
Juniper Networks, Inc. v.Monarch Networking Solutions LLC
· IPR2024-00561
Monarch’s response to Juniper’s IPR argues that the challenged claims of U.S. Patent 8,130,775 are not obvious, emphasizing that prior‑art references do not disclose a shared link between two pseudo‑wires.
patent · Aug 2, 2024
Juniper Networks, Inc. v.Monarch Networking Solutions LLC
· IPR2024-00561
Monarch Networking’s sur‑reply defends the validity of its MPLS‑pseudowire patent against Juniper’s IPR petition, arguing the prior art does not disclose the claimed shared‑link architecture.
patent · Aug 2, 2024
Juniper Networks, Inc. v.Monarch Networking Solutions LLC
· IPR2024-00561
Monarch’s preliminary response urges the PTAB to deny Juniper’s IPR petition, arguing the cited references do not teach a shared link between two pseudo‑wires and that the petition repeats arguments already considered by the USPTO.
patent · Aug 2, 2024
Nexus Pharmaceuticals LLC v.Exela Pharma Sciences, LLC
· PGR2024-00016
Nexus Pharmaceuticals has filed a PGR petition challenging all 30 claims of Exela Pharma Sciences' L‑cysteine parenteral nutrition patent, asserting lack of enablement, insufficient written description, and, alternatively, obviousness over the Sandoz label.
patent null · Aug 2, 2024
Juniper Networks, Inc. v.Monarch Networking Solutions LLC
· IPR2024-00561
Juniper Networks challenged U.S. Patent 8,130,775 in an IPR petition, arguing that claims 1 and 6 are obvious based on prior art combinations. The petitioner asserts that combining Wainner/Bocci or Kamite/Bocci renders the claimed network technology conventional and predictable.
patent instituted · Aug 2, 2024
Juniper Networks, Inc. v.Monarch Networking Solutions LLC
· IPR2024-00561
Juniper Networks challenged U.S. Patent 8,130,775 in an IPR, arguing that claims 1 and 6 were obvious over combinations of Wainner, Bocci, and Kamite. The Board found the merits strong and ruled to institute the proceeding, noting prior art was not substantively analyzed by the Examiner.
patent null · Aug 2, 2024
DISH Network L.L.C. et al. v.Entropic Communications LLC
· IPR2024-00555
DISH Network L.L.C. initiated an IPR challenging patent 8320566 owned by Entropic Communications LLC, arguing that the claims are obvious under 35 U.S.C. § 103. The petitioner relies on multiple combinations of prior art references, including Cleveland/Hayashino and Scheim/Tzannes, to demonstrate non-patentability in the field of OFDMA/Scrambling.
patent denied · Aug 2, 2024
Nexus Pharmaceuticals LLC v.Exela Pharma Sciences, LLC
· PGR2024-00016
Nexus Pharmaceuticals' PGR challenge against Exela Pharma Sciences was denied institution because the arguments regarding enablement, written description, and obviousness were largely identical to those previously presented during prosecution. The Board found that the Patent Owner successfully demonstrated how process controls overcome prior rejections, leading to a denial of the petition under § 325(d).
patent instituted · Aug 2, 2024
Juniper Networks, Inc. v.Monarch Networking Solutions LLC
· IPR2024-00561
Juniper Networks successfully petitioned to institute IPR against Monarch Networking Solutions LLC regarding packet switching claims (Claims 1 and 6). The Board found sufficient evidence of obviousness over combinations of prior art references, including Wainner/Bocci and Kamite/Bocci.
patent denied · Aug 2, 2024
DISH Network L.L.C. et al. v.Entropic Communications LLC
· IPR2024-00555
DISH Network L.L.C.'s IPR petition against Entropic Communications LLC's '566 patent was denied by the PTAB, finding no reasonable likelihood of prevailing on any claim. The Board rejected all asserted grounds under 35 U.S.C. § 103 regarding obviousness over various prior art combinations in OFDMA/Spectrum Sharing technology.
patent final · Aug 2, 2024
Juniper Networks, Inc. v.Monarch Networking Solutions LLC
· IPR2024-00561
The PTAB issued a Final Written Decision finding that claims 1 and 6 of the patent were unpatentable over prior art references Wainner and Bocci. The Board agreed with the Petitioner's argument that combining these references rendered the claimed method obvious, particularly regarding shared link functionality in pseudo-wires.
patent · Aug 1, 2024
Ilooda Co., Ltd. et al. v.Serendia, LLC
· IPR2024-00386
Serendia seeks Director Review to overturn the Board’s institution of an IPR against its dermatology device patent after the ITC affirmed the patent’s validity, arguing the Board abused discretion and that extraordinary circumstances exist.
patent terminated or settled · Aug 1, 2024
Ilooda Co., Ltd. et al. v.Serendia, LLC
· IPR2024-00386
EndyMed Medical and Serendia have settled their dispute over U.S. Patent 9,480,836 and jointly moved to terminate the inter partes review. The Board is asked to dismiss the proceeding before any oral hearing or final decision.
patent terminated or settled · Aug 1, 2024
Ilooda Co., Ltd. et al. v.Serendia, LLC
· IPR2024-00386
Endymed Medical and Serendia settled their inter partes review of U.S. Patent 9,480,836, leading the PTAB to terminate the proceeding under 35 U.S.C. § 317.
patent terminated or settled · Aug 1, 2024
Ilooda Co., Ltd. et al. v.Serendia, LLC
· IPR2024-00386
The PTAB granted a joint motion to terminate the IPR for Jeisys Medical Inc. after the parties settled their dispute. The settlement agreement was ordered to be kept confidential, and the proceeding remains open only for EndyMed petitioners.
patent · Aug 1, 2024
Ilooda Co., Ltd. et al. v.Serendia, LLC
· IPR2024-00386
Ilooda and Serendia filed a joint motion to terminate Ilooda's participation in an IPR over a dermatology device patent, citing a settlement that resolves the dispute.
patent terminated or settled · Aug 1, 2024
Ilooda Co., Ltd. et al. v.Serendia, LLC
· IPR2024-00386
Jeisys Medical and Serendia have settled their dispute over U.S. Patent 9,480,836 and jointly moved to terminate the inter partes review. The Board is asked to end the proceeding before any substantive briefing or hearing.
patent terminated or settled · Aug 1, 2024
Jeisys Medical Inc. et al. v.Serendia, LLC
· IPR2024-00384
Serendia and Jeisys Medical settled their IPR dispute over U.S. Patent 9,320,536, leading the PTAB to terminate the proceeding.
